Benchling and Moderna Expand Collaboration on AI-Driven Research Benchling, the leading R&D platform for the biotech industry, has announced an expanded partnership with Moderna. Initially, Benchling supported Moderna’s technical development teams, including those in analytical development, technical operations, process development, and formulations. Now, this collaboration is broadening to encompass Moderna’s entire research organization, bringing hundreds of scientists onto a unified, AI-ready digital platform designed to expedite discovery and innovation. "Moderna’s foundational belief is that technology and science, when combined, drive groundbreaking advancements in medicine," said Wade Davis, Senior Vice President of Digital at Moderna. "AI presents unprecedented opportunities, but to harness its full potential, we need transformative ways of working. Benchling is addressing these challenges effectively. Our collaboration ensures that scientists have a robust foundation for AI, while our computational scientists and engineers are empowered to perform cutting-edge research." A New Standard for Digital Transformation in Biotech The core objectives of this digital transformation include consolidating systems to create a seamless user experience, automating scientific workflows, and standardizing data into formats compatible with AI. These goals are crucial for enhancing productivity and efficiency in the R&D process. "Research and development teams face relentless pressure to innovate and operate more efficiently," remarked Sajith Wickramasekara, CEO and co-founder of Benchling. "AI and automation hold the key to unprecedented productivity, but they require the appropriate infrastructure. Moderna and Benchling are setting a new benchmark for the future of R&D—fully digital, deeply integrated, and intelligent at scale." Innovating the Infrastructure for AI in Biotech Moderna’s research and technical development teams needed a flexible system capable of scaling alongside their growing pipeline. Benchling’s digital platform meets this demand by offering a balanced approach that combines agility with pre-built scientific workflows. Moderna’s digital teams leverage Benchling’s developer platform to construct and deploy custom workflows, automate template creation, and integrate proprietary machine learning models. This move significantly cuts down setup time for new workflows and supports high-throughput processing of experimental data, allowing digital teams to focus on innovation rather than system maintenance. As Benchling’s platform expands across Moderna’s research organization, scientists can now design experiments, track samples, and analyze results within a single, cohesive system. This integration resolves a longstanding industry issue: the challenge of combining structured and unstructured data from various research environments. By laying a robust groundwork, the platform paves the way for AI-driven analysis across different therapeutic areas. Through their collaboration, Benchling and Moderna are not only revolutionizing their own R&D processes but also setting a new standard for the digital infrastructure that will power AI-driven biotech research in the future.